NasdaqGS:BBIOBiotechs
A Look At BridgeBio Pharma (BBIO) Valuation After Positive Phase 3 PROPEL 3 Achondroplasia Results
BridgeBio Pharma (BBIO) has become a focus for investors after reporting positive topline results from its global Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia.
See our latest analysis for BridgeBio Pharma.
The positive PROPEL 3 data sits alongside a very strong 1-year total shareholder return of 113.72% and a roughly 7x total shareholder return over 3 years. The 90-day share price return of 15.73% suggests momentum has recently picked up again, despite a softer...